HONG KONG, March 26 /PRNewswire/ --
Multiple presentations by interventional cardiologists at the American College of Cardiology's 57th Annual Scientific Session (ACC.08) will feature OrbusNeich's Genous Bio-engineered R stent.
The presentations at the conference, which will take place March 29 - April 1 in Chicago, include:
-- "Six Months Clinical Outcome of the Academic Medical Center (AMC) Single Center Real World Experience on Stent Thrombosis in Patients Treated With a Genous EPC Capturing Stent" by Margo Klomp of AMC from 8 a.m. -- 5 p.m. CDT on March 29 -- "Comparison of 18-Month Clinical Outcomes of Endothelial Progenitor Cell Capture Stent vs. Sirolimus-Eluting Bioabsorbable Polymer-Coated Stent vs. Bare Metal Stents in Patients Undergoing Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction" by Eric Chong of NUH from 8 a.m. -- 5 p.m. CDT on March 29 -- "Pro Healing Approach" by Robbert De Winter of AMC from 10:40 -- 10:50 a.m. CDT on March 29 -- "Percutaneous Coronary Intervention Utilizing a New Endothelial Progenitor Cells Antibody-coated Stent: A Prospective Single-center Registry in High Risk Patients" by Giuseppe Patti of Campus Bio- Medico University from 8 a.m. -- 5 p.m. CDT on March 29 -- "Improved Endothelial Coverage of Drug-Eluting Stents When Overlapped with an Endothelial Progenitor Cell Capture Stent" by Gaku Nakazawa of CVPath Institute from 1:36 -- 1:42 p.m. CDT on March 30
Unlike drug-eluting stents, Genous, which is coated with an antibody, captures a patient's endothelial progenitor cells (EPCs) to accelerate the natural healing process. EPCs circulate in the bloodstream and are involved in the repair of blood vessels. When attracted to the surface of Genous, EPCs rapidly form an endothelial layer over the stent that provides protection against thrombus and minimizes restenosis.
OrbusNeich designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. The company's product portfolio includes the Genous(TM) Bio-engineered R stent(TM), an antibody-coated device that is the first-ever stent to capture a patient's endothelial progenitor cells (EPCs) to accelerate the natural healing process following placement. Other products are stents, balloons and guiding catheters marketed under the names of Blazer(TM), R stent(TM), Sapphire(TM), Avita(TM), Avita HP(TM), SafeCut(TM), Lumina(TM) and Saffron.
A global company, OrbusNeich is headquartered in Hong Kong and has operations in Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Shenzhen, China. OrbusNeich, which has provided cardiology devices to physicians through its predecessor companies since 1979, today supplies products in more than 60 countries. For more information, visit www.OrbusNeich.com.
Web site: http://www.OrbusNeich.com
David Schull of Russo Partners LLC, Office +1-212-845-4271, Mobile +1-858-717-2310, firstname.lastname@example.org